This ES–KES joint symposium provides a comprehensive overview of current clinical challenges and advances in antiresorptive therapy. Topics include management of treatment sequences following denosumab discontinuation, the impact of antiresorptive therapies on systemic health and longevity beyond fracture prevention, and their role in cancer-related bone diseases. The session aims to enhance clinical decision-making and translational understanding for both clinicians and researchers.

The rising stars in Endocrinology session presents cutting-edge research and clinical insights from emerging leaders. Topics include immune checkpoint inhibitor–related endocrine dysfunction, disease-modifying strategies in Graves’ disease and thyroid eye disease, advances in fracture risk assessment, and prevention of rebound phenomena after denosumab. The session emphasizes future directions in endocrinology through clinically relevant, translational perspectives.

This PCEDM–KES joint symposium promotes academic exchange with the Philippines, an active international participant at SICEM. It focuses on practical, evidence-based management of common endocrine diseases in Asian populations. Key topics include sequential therapy in osteoporosis, subclinical hypothyroidism, and newer antidiabetic agents. Speakers present guideline-based, clinically applicable treatment strategies. The session supports effective clinical decision-making and future collaboration.